Sermorelin was approved once. A lot has changed.
Welcome. An old approval can sound like an answer to a new question. With Sermorelin, the dates matter. Let’s start with the children’s treatment and see what happened next.

1997
The children’s chapter
It started with a specific growth problem
Sermorelin asks a gland beneath the brain to release growth hormone. The gland is called the pituitary. Sermorelin isn’t growth hormone itself. Its treatment approval in 1997 was for children with growth failure and an unexplained shortage of that hormone.
A study in children with that shortage found faster height growth during the first treatment year. That’s a real finding, with a clear purpose. It doesn’t answer an adult’s questions about sleep, energy or body fat. The children’s history keeps the result with the children who were studied.
2008–2013
Leaving the market
Leaving sale wasn’t the same as a safety withdrawal
The maker said it was discontinuing the products in 2008. The approvals ended in 2009. Then, in 2013, the FDA found that the old products hadn’t left sale for safety or effectiveness reasons. Those are three separate events.
The 2013 finding still doesn’t tell us why the maker stopped selling. The official notices leave that reason unstated, so there’s no need to guess. Today’s compounded Sermorelin is not FDA-approved.
2025
Compounding today
A prescription and an approval are different things
Compounding means preparing a medicine for a particular need. The FDA’s January 2025 guidance explains rules for using ingredients in patient-specific compounding. It doesn’t approve every medicine made under those rules. Compounded medicines are not FDA-approved.
The access page explains why an ingredient from an old approved drug can matter here. The rules may offer a route to compounding, with conditions attached. A prescription alone doesn’t establish that every condition has been met.
What does that leave you asking today?
For an adult, the starting question is what treatment is meant to help with. Then comes the evidence: did researchers study that outcome in similar people? An approval for childhood growth can’t answer those questions by itself.
The adult studies found hormone changes, with important limits. Older work also reported flushing and pain at the injection site, while long-term adult safety remains uncertain. The safety page covers those gaps; the trial doses page explains why a research dose isn’t a personal plan.